These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20856184)

  • 1. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
    Plesnicar BK
    Psychiatr Danub; 2010 Sep; 22(3):413-7. PubMed ID: 20856184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of venlafaxine extended release in elderly depressed patients.
    Ibor JJ; Carrasco JL; Prieto R; García-Calvo C;
    Arch Gerontol Geriatr; 2008; 46(3):317-26. PubMed ID: 17617478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
    Allard P; Gram L; Timdahl K; Behnke K; Hanson M; Søgaard J
    Int J Geriatr Psychiatry; 2004 Dec; 19(12):1123-30. PubMed ID: 15526307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder.
    Hung CI; Wang SJ; Liu CY
    Depress Anxiety; 2009; 26(6):583-91. PubMed ID: 19242983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of open-label venlafaxine in subjects with major depressive disorder: associations with neuroendocrine response to serotonergic and noradrenergic probes.
    Grossman R; Reynolds D; Goodman M; New A; Silverman J; Schmeidler J; Mitropoulou V; Siever LJ
    Psychiatry Res; 2004 Sep; 128(2):203-6. PubMed ID: 15488964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effects of venlafaxine extended release for patients with depressive and anxiety disorders in the German outpatient setting - results of 2 observational studies including 8500 patients].
    Anghelescu IG; Dierkes W; Volz HP; Loeschmann PA; Schmitt AB
    Fortschr Neurol Psychiatr; 2009 Nov; 77(11):646-54. PubMed ID: 19890774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms.
    Huang X; Li C; Luo YL; Wang B; Ji JL
    Neuroreport; 2013 May; 24(7):364-9. PubMed ID: 23511776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression in primary care: effectiveness of venlafaxine extended-release in elderly patients; Observational study.
    Cervera-Enguix S; Baca-Baldomero E; Garcia-Calvo C; Prieto-López R;
    Arch Gerontol Geriatr; 2004; 38(3):271-80. PubMed ID: 15066313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.